These patients had not been treated with antiretroviral drugs. Additionally, in an open-label, triple combination trial involving 32 patients, combination therapy involving Norvir and the nucleoside analogues AZT and ddC nearly doubled the median CD4 cell count from baseline. The triple therapy also caused reductions in the number of HIV RNA particles in the blood by week 20. Norvir had a favorable safety profile in clinical trials. Norvir should not be used in combination with many highly metabolized medications known to produce serious or life-threatening adverse events.
Specific information is available in the prescribing information.
Eleven years ago today Abbott received clearance from the FDA to market the world's first HIV test. Abbott Laboratories is a worldwide manufacturer of health care products, employing 50,000 people worldwide. The company researches, develops, and markets pharmaceutical, diagnostic, nutritional and hospital products. Please contact us with any comments, problems or bugs.